Document Detail

Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response.
MedLine Citation:
PMID:  21986085     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: To assess the safety and efficacy of ranibizumab in patients who had inadequate response to pegaptanib or bevacizumab.
PATIENTS AND METHODS: In this single-center study, 19 patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) previously treated with pegaptanib (n = 1), bevacizumab (n = 13), or both (n = 5) received 12 monthly ranibizumab injections (0.5 mg). Outcomes were measured from start of previous therapy (baseline) to start of ranibizumab treatment (day 0) through 12 months.
RESULTS: No drug- or injection-related adverse events and no serious adverse events were reported. At 6 and 12 months, 4 and 5 patients gained 3 or more lines of VA, respectively; 3 patients lost less than 3 lines of VA at 6 months, and 6 patients lost less than 3 lines at 12 months. At 6 and 12 months, VA increased by a mean (± standard error of the mean) of 2.06 ± 1.23 and 1.17 ± 0.62 lines, respectively. Central retinal thickness decreased by a mean of 62.65 ± 22.46 and 62.16 ± 29.20 μm at months 6 and 12, respectively. When stratified by pigment epithelial detachment (PED) status, patients without PED had better visual and anatomical outcomes than patients with PED.
CONCLUSION: Ranibizumab has favorable safety and efficacy profiles for patients with AMD without previous response to pegaptanib or bevacizumab.
Richard S Kaiser; Omesh P Gupta; Carl D Regillo; Allen C Ho; Mitchell S Fineman; James F Vander; J Arch McNamara; Gary C Brown
Related Documents :
21601395 - Tinnitus retraining therapy using portable music players.
9872515 - Relationship between the eradication of helicobacter pylori and the healing pattern of ...
8221815 - Six-month maintenance treatment of duodenal ulcer with sucralfate: influence on antral ...
21622545 - Does the outcome justify an oral-first treatment strategy for management of pulmonary a...
22549915 - Antihelical shaping of prominent ears using conchal cartilage-grafting adhesion.
17002625 - A randomized, controlled phase iii trial of therapeutic plasma exchange with fresh-froz...
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-10-13
Journal Detail:
Title:  Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye     Volume:  43     ISSN:  1938-2375     ISO Abbreviation:  Ophthalmic Surg Lasers Imaging     Publication Date:    2012 Jan-Feb
Date Detail:
Created Date:  2012-01-18     Completed Date:  2012-03-27     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101155780     Medline TA:  Ophthalmic Surg Lasers Imaging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  13-9     Citation Subset:  IM    
Copyright Information:
Copyright 2012, SLACK Incorporated.
Retina Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects,  therapeutic use*
Aptamers, Nucleotide / therapeutic use*
Drug Substitution
Intravitreal Injections
Middle Aged
Tomography, Optical Coherence
Treatment Failure
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Wet Macular Degeneration / drug therapy*,  physiopathology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determination of Lithium in Mineral Water Samples by X-ray Fluorescence Spectrometry.
Next Document:  Minor Interference of Cross-Reactive Carbohydrates with the Diagnosis of Respiratory Allergy in Stan...